You are here: Industry Insights > Novartis

News List

Torrent completes acquisition of Novartis brands financialexpress
May 10, 2017
The two brands are widely prescribed by gynaecologists for the management of abnormal uterine bleeding, post menopausal symptoms and infertility
Novartis scoops up rights to NASH drug pharmatimes
May 05, 2017
Novartis has exercised an option giving it global development and commercialisation rights to an experimental drug...
Novartis exercises exclusive option agreement with Conatus for the treatment of NASH worldpharmanews
May 05, 2017
Novartis announced today that it has notified Conatus Pharmaceuticals Inc., of its exercise of the option to an exclusive license for the global development and commercialization of emricasan, under the option, collaboration and license agreement signed w
Novartis real-world data confirms benefit of Gilenya in relapsing MS europeanpharmaceuticalreview
May 02, 2017
Novartis announced data from the Phase IV Multiple Sclerosis and clinical outcome and MRI in the US (MS-MRIUS) study, which confirmed the effectiveness of Gilenya (fingolimod) in the real-world setting, supporting previous findings from Phase III trials.
Novartis, Amgen expand agreement to commercialize migrane drug biospectrumasia
April 28, 2017
The companies had inked a deal in 2015 for commercialization of the drug, involving joint development and commercialisation of pioneering treatments in the field of Alzheimer’s disease and migraine
Novartis and Amgen expand global collaboration to commercialise AMG 334 pharmaceutical-technology
April 27, 2017
Novartis has entered an expanded commercialisation agreement with Amgen for AMG 334 (erenumab), which is being...
Novartis Reports 1st Quarter Results americanpharmaceuticalreview
April 27, 2017
Novartis announced financial results for the first quarter of 2017.
Novartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activit worldpharmanews
April 25, 2017
Novartis today announced data from the Phase IV Multiple Sclerosis and clinical outcome and MRI in the US (MS-MRIUS) study, which confirmed the effectiveness of Gilenya® (fingolimod) in the real-world setting, supporting previous findings from Phase III t
Novartis’ eltrombopag in SAA pharmatimes
April 21, 2017
Novartis has announced the publication of data showing high response rates in patients with the rare...
NIH study shows Novartis drug eltrombopag improves responses in severe aplastic anemia europeanpharmaceuticalreview
April 21, 2017
Novartis announced the publication of a study conducted by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) demonstrating that 58% of patients with treatment-naïve severe aplastic anemia (SAA) achieved compl

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page